Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention.

doi:10.1016/j.jalz.2010.06.003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention.

Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Jul 2011

Schipper Hyman M

Abstract excerpt

Current practice guidelines advocate apolipoprotein E (APOE) genotyping in cases of dementia and mild cognitive impairment and also in asymptomatic participants within the context of clinical/epidemiological research. APOE genotyping is not recommended for prognostication in cognitively intact persons outside the research arena. On the basis of emerging developments, in this article, we revisit the notion that...

Topics

Alzheimer Disease
Apolipoproteins E
Genotype
Humans
Neuropsychological Tests
Risk Assessment

Source

Open in PubMed

Identifiers

PMID: 21665554
DOI: 10.1016/j.jalz.2010.06.003

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics